Drug intelligence / Profile preview

18F-FC505

Development stage: Preclinical
Lead developer: FutureChem
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-FC505 is a fluorine-18 ([18F]) labeled small molecule radiopharmaceutical under development by FutureChem Pharma as a diagnostic imaging agent. It is specifically designed for Positron Emission Tomography (PET) to detect and evaluate atherosclerotic plaques. The tracer is intended to identify vulnerable plaques that are at high risk of rupture, potentially aiding in the prevention of myocardial infarction and stroke. Currently in the preclinical stage, 18F-FC505 leverages the high sensitivity of PET imaging to provide detailed information on plaque composition or inflammatory activity within the arterial wall.

Other names: [18F]FC505

Beyond the preview

Go deeper on 18F-FC505.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-FC505.

Explore the full profile